184P - 18F-BMS-986192 PET for predicting clinical response to immunotherapy in NSCLC: A novel approach beyond PD-L1 immunohistochemistry

Background

In non-small cell lung cancer (NSCLC), 20% of patients respond durably to immunotherapy. Heterogeneity possibly limits the power of PD-L1 immunohistochemistry (IHC). To address this challenge, we investigated the use of PD-L1 positron emission tomography (PET) using ¹⁸F-BMS-986192.

Methods

80 patients with stage IV NSCLC were enrolled, and were treated with nivolumab with or without chemotherapy or ipilimumab. All patients underwent 18^F-FDG and 18^F-BMS-986192 PET scans. Malignant lesions were identified via FDG-PET and delineated using PDL1-PET. Progression-free survival (PFS) at 9 months was selected as the primary endpoint, reflecting the waning effects of chemotherapy. PFS and overall survival (OS) were analyzed concerning PD-L1 uptake on PET scans and compared to PD-L1 immunohistochemistry (IHC) scores using the 22C3 antibody.

Results

Tracer uptake across all lesions per patient with PFS ≥9 months vs PFS

Conclusions

PD-L1 PET using 18F-BMS-986192 shows predictive potential. In this cohort, PD-L1-PET demonstrated superior predictive value for PFS and OS compared to PD-L1 IHC. The applicability in daily clinical practice should be investigated further since it is a laborintensive technique and needs to be validated in a more homogeneous treatment cohort.

Funding

BMS.

Disclosure

All authors have declared no conflicts of interest.